Galen Holdings last month received Food and Drug Administration approval for its Femring (estradiol acetate vaginal ring), the first vaginal estrogen product indicated to treat both hot flashes and vaginal symptoms associated with menopause. Galen plans to introduce Femring in June.
In other news, U.S. antitrust enforcers cleared Pfizer's proposal to sell three of its women's health drugs to Galen, including two oral contraceptives--Estrostep and Loestrin--and the hormone replacement therapy drug Femhrt, for a reported $359 million initially.
Galen will pay an additional $125 million if Estrostep and Femhrt fend off challenges from generic drug makers until their patents expire in 2008 and 2010, respectively, Pfizer has reported.
COPYRIGHT 2003 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2003 Gale Group
Contact
Home
A
E-Base